Hvsen Biotechnology Co., Ltd. (300871.SZ) develops, manufactures, and sells in-vitro diagnostic reagents and instruments primarily focused on clinical chemistry, immunoassay, and molecular diagnostics; its core product portfolio includes chemiluminescence immunoassay analyzers and reagents under the HYBRiD brand, biochemical analyzers, PCR-based nucleic acid extraction systems, and supporting consumables such as test kits for tumor markers, infectious diseases, and cardiac biomarkers. The company serves hospitals, clinics, and diagnostic laboratories in China and select international markets including Southeast Asia and Europe. Founded in 2000 and headquartered in Wuhan, China, Hvsen operates through subsidiaries like Wuhan Huasen Biological Technology Co., Ltd., emphasizing automated diagnostic solutions for high-throughput testing.
In the diagnostics industry, Hvsen targets secondary and tertiary hospitals as primary customers, with expanding reach into primary care facilities and export channels. The company recently launched advanced chemiluminescence immunoassay systems in 2024, enhancing throughput and sensitivity for multi-parameter testing, alongside a strategic partnership with a leading Southeast Asian distributor to bolster regional market penetration. No major acquisitions or funding rounds reported in the last two years, though operational expansions include upgraded manufacturing facilities in Wuhan to meet rising domestic demand for COVID-19 and post-pandemic testing solutions.